$MTNB 2.41 0.00 0.00 15,164 2.27 2.49 M
Post# of 23083
(Total Views: 239)
Posted On: 06/05/2017 8:42:01 AM
$MTNB 2.41 0.00 0.00 15,164 2.27 2.49
Matinas BioPharma Files 8K - Regulation FD >MTNB
39 minutes ago - DJNF
Matinas BioPharma Holdings Inc. (MTNB) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on June 03, 2017.
On June 3, 2017, Matinas BioPharma Holdings, Inc. (the "Company"
issued a press release to report interim results from the Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis, which is being conducted by the National Institutes of Health. The press release is attached hereto as Exhibit 99.1.
The Company intends to use the presentation included as Exhibit 99.2 to this report in connection with its investor conference call on June 5, 2017.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act" , or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/158255...382_8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/158255...-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a compan
Matinas BioPharma Files 8K - Regulation FD >MTNB
39 minutes ago - DJNF
Matinas BioPharma Holdings Inc. (MTNB) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on June 03, 2017.
On June 3, 2017, Matinas BioPharma Holdings, Inc. (the "Company"
issued a press release to report interim results from the Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis, which is being conducted by the National Institutes of Health. The press release is attached hereto as Exhibit 99.1. The Company intends to use the presentation included as Exhibit 99.2 to this report in connection with its investor conference call on June 5, 2017.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"
, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/158255...382_8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/158255...-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a compan
(1)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'